Evenity (Romosozumab)
romosozumab 105 mg/1.17 mL injection, 2 x 1.17 mL syringes · INJECTION · PBS code 14641N
AUTHORITY_REQUIREDWhat it costs
AU$352.24 PBS-determined price per 2 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2024-11-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe established osteoporosis
Initial treatment - First-line therapy
Patient must not have received PBS-subsidised treatment with any of: (i) anti-resorptive therapy, (ii) teriparatide, (iii) romosozumab; AND
Patient must be at very high risk of fracture; AND
Patient must have a Bone Mineral Density (BMD) T-score of -2.5 or less; AND
Patient must have had a symptomatic fracture due to minimal trauma; AND
Patient must have had at least 1 hip or symptomatic vertebral fracture in the previous 24 months; or
Patient must have had at least 2 fractures including 1 symptomatic new fracture in the previous 24 months; AND
The treatment must be the sole PBS-subsidised therapy for this condition; AND
The treatment must not exceed a lifetime maximum of 12 months of PBS and non-PBS-subsidised therapy; AND
Must be treated by a consultant physician.
Details of fracture history including the date(s), site(s), the symptoms associated with the fracture(s) and the score of the qualifying BMD measurement must be provided at the time of application.
A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
Anti-resorptive therapies for osteoporosis include alendronate sodium, risedronate sodium, raloxifene hydrochloride, denosumab and zoledronic acid.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe established osteoporosis
Continuing treatment - First-line therapy
Patient must have previously received PBS-subsidised treatment with this drug for this condition as first-line therapy; AND
The treatment must be the sole PBS-subsidised therapy for this condition; AND
The treatment must not exceed a lifetime maximum of 12 months of PBS and non-PBS-subsidised therapy; AND
Must be treated by a medical practitioner identifying as either: (i) a consultant physician, (ii) a general practitioner.
Sponsor: Amgen Australia Pty Limited ABN 31 051 057 428
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.